-
Mashup Score: 8Gastrointestinal Cancers Symposium | ASCO Daily News - 1 month(s) ago
The latest scientific coverage and expert insights from the ASCO Gastrointestinal Cancers Symposium, all in one place.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 11Everolimus Plus Lanreotide Extends PFS in Patients With Aggressive Gastroenteropancreatic Neuroendocrine Tumors - 1 month(s) ago
The phase 3 STARTER-NET trial found that everolimus plus lanreotide more than doubles progression-free survival among patients with aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus everolimus therapy alone, and has a manageable safety profile (Abstract 652). The trial focused on patients with unresectable or recurrent grade 1 or 2 GEP-NETs with poor prognostic factors, for whom effective treatments are currently lacking.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: https://t.co/LyF50SL8UI #ASCODailyNews #GICSM https://t.co/k6CBAIzzut
-
-
Mashup Score: 0Colorectal Cancer Screening and Early Detection: Expanding Options and Increasing Adherence With Noninvasive Tests - 1 month(s) ago
Colorectal cancer screening and early detection options are moving beyond colonoscopy and becoming less invasive. Can more sensitive and specific blood- and stool-based tests increase adherence to screening recommendations?
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
@doclauravater For more, @AasmaShaukatMD’s recent editorial for #ASCODailyNews discusses how these new tests have the potential to increase CRC screening adherence and early cancer detection: https://t.co/yHPbriuSaI
-
-
Mashup Score: 58Study Reveals Decisional Regret After Surgery Among Patients With Pancreatic Ductal Adenocarcinoma - 2 month(s) ago
Some patients with localized pancreatic ductal adenocarcinoma who have had surgical resection may later regret their decision if they experience complications (Abstract 699).
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Is surgery always the right answer? While surgery offers the only chance for a cure in #PancreaticCancer , a study found that 19 out of 45 patients experienced significant regret after undergoing surgery. #pancchat https://t.co/mTD3hDZfy5 https://t.co/BlW9XcTJgp
-
-
Mashup Score: 10Everolimus Plus Lanreotide Extends PFS in Patients With Aggressive Gastroenteropancreatic Neuroendocrine Tumors - 2 month(s) ago
The phase 3 STARTER-NET trial found that everolimus plus lanreotide more than doubles progression-free survival among patients with aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus everolimus therapy alone, and has a manageable safety profile (Abstract 652). The trial focused on patients with unresectable or recurrent grade 1 or 2 GEP-NETs with poor prognostic factors, for whom effective treatments are currently lacking.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
New research just presented at #GI25: STARTER-NET trial shows everolimus + lanreotide more than doubles PFS vs everolimus monotherapy among pts w/ aggressive GEP-NETs: https://t.co/LyF50SL8UI #ASCODailyNews #GICSM https://t.co/k6CBAIzzut
-
-
Mashup Score: 23Quality-of-Life and Geriatric Assessments Correlate With Survival in Elderly Patients With Pancreatic Cancer - 2 month(s) ago
The GIANT trial secondary analysis shows that baseline quality of life and geriatric assessments strongly correlate with survival outcomes in elderly patients with newly diagnosed metastatic pancreatic adenocarcinoma treated with dose-reduced chemotherapy (Abstract 676).
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Quality of life evaluations & geriatric assessments are strongly correlated w/ survival in vulnerable older patients w/ newly diagnosed metastatic #PancreaticCancer, according to new data presented at #GI25: https://t.co/XPBD2pn9Tm https://t.co/8RlC2zz6Vs
-
-
Mashup Score: 1Understanding Young Lung Cancer: The Time Is Now - 2 month(s) ago
Although a lung cancer diagnosis is unsettling for all, patients who are 50 years old or younger face unique challenges, as a cancer diagnosis is not age normative and is profoundly disruptive.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Understanding Young Lung Cancer: The Time Is Now https://t.co/TGgxLtQm5j
-
-
Mashup Score: 8Gastrointestinal Cancers Symposium | ASCO Daily News - 2 month(s) ago
The latest scientific coverage and expert insights from the ASCO Gastrointestinal Cancers Symposium, all in one place.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Research from #GI24 is now available! #ASCODailyNews is covering just-released abstracts from the upcoming Symposium, and you can read all the advance articles now: https://t.co/A037RntyKB #gicsm #OncTwitter https://t.co/kwyFjBDCEr
-
-
Mashup Score: 11Breast Cancer Mortality by Clinical Stage: Low-Risk Cancers Cause Most Breast Cancer Deaths Each Year - 2 month(s) ago
Paradoxically, most annual breast cancer deaths in the United States result from low-risk stage I or II cancers. Can novel strategies—such as molecular relapse monitoring and earlier therapy administration before clinical relapse—reduce mortality from these low-risk cancers?
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Paradoxically, most annual #BreastCancer deaths in the U.S. result from low-risk stage I or II cancers, reports Dr. Lajos Pusztai of @YaleCancer @YaleBreast. His new editorial for #ASCODailyNews examines this fact & shares results from his recent study: https://t.co/qHayaenGvA https://t.co/deOkGPGvyg
-
-
Mashup Score: 133ctDNA Assays: Exploring Their Clinical Use in Oncology Care - 2 month(s) ago
ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum because they answer various clinical questions (Figure 1). Their use is moving up to earlier-stage settings from their initial development and approval for patients with metastatic cancer. As these agents enter more prominent clinical use, it is vital for clinicians to understand that there are different kinds of ctDNA assays.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
#ctDNA🧬can be broadly divided into tumor-informed🔬🆚tumor-naive🩸 platforms. Different lenses🔎of looking at the cancer through a blood draw. Depending on the clinical question & tumor type, different types available. #ASCODailyNews @ASCO @DrawImpacts https://t.co/o5LnECXNn0 https://t.co/Ct5kVwkh7G
-
Research from #GI24 is now available! #ASCODailyNews is covering just-released abstracts from the upcoming Symposium, and you can read all the advance articles now: https://t.co/A037RntyKB #gicsm #OncTwitter https://t.co/kwyFjBDCEr